Geographic Distribution of the 20210 G
to A Prothrombin Variant

F. R. Rosendaal¹, ², C. J. M. Doggen¹, A. Zivelin³, V. R. Amuda⁴, M. Aiach⁵, D. S. Siscovick⁶, A. Hillaire⁷, H. H. Watzke⁸, F. Bernardi⁹, A. M. Cumming¹⁰, F. E. Preston¹¹, P. H. Reitsma¹²

From the¹Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands; ²Department of Hematology, Leiden University Medical Centre, Leiden, The Netherlands; ³Institute of Thrombosis and Hemostasis, Department of Hematology, Sheba Medical Centre, Tel-Hashomer, Israel; ⁴Hematology-Hemotherapy Centre, State University of Campinas, Campinas, Brazil; ⁵Laboratory of Hemostasis, Broussais Hospital, Paris, France; ⁶Department of Epidemiology, Department of Internal Medicine, University of Washington, Seattle, USA; ⁷Department of Clinical Chemistry, Lund University, Malmö, Sweden; ⁸Department of Hematology and Hemostasiology, University of Vienna, Vienna, Austria; ⁹Department of Biochemistry and Molecular Biology, University of Ferrara, Ferrara, Italy; ¹⁰Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom; ¹¹Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, United Kingdom; ¹²Laboratory for Experimental Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands

Summary

A variant in prothrombin (clotting factor II), a G to A transition at nucleotide position 20210, has recently been shown to be associated with the prothrombin plasma levels and the risk of both venous and arterial thrombosis. The purpose of this study was to investigate the prevalence of carriership of this mutation in various populations.

We combined data from 11 centres in nine countries, where tests for this mutation had been performed in groups representing the general population. We calculated an overall prevalence estimate, by a precision-weighted method, and, since the distribution of the prevalences did not appear homogeneous, by an unweighted average of the prevalences. We examined differences in the prevalences by geographical location and ethnic background as a possible explanation for the heterogeneity.

Among a total of 5527 individuals who had been tested, 111 heterozygous carriers of the 20210A mutation were found. The prevalence estimates varied from 0.7 to 4.0 between the centres. The overall prevalence estimate was 2.0 percent (CI95 1.4-2.6%). The variation around the summary estimate appeared more than expected by chance alone, and this heterogeneity could be explained by geographic differences. In southern Europe, the prevalence was 3.0 percent (CI95 2.3 to 3.7%), nearly twice as high as the prevalence in northern Europe (1.7%, CI95 1.3 to 2.2%). The prothrombin variant appeared very rare in individuals from Asian and African descent.

The 20210A prothrombin variant is a common abnormality, with a prevalence of carriership between one and four percent. It is more common in southern than in northern Europe. Since this distribution within Europe is very different to that of another prothrombotic mutation (factor V Leiden or factor V R506Q), founder effects are the most likely explanation for the geographical distribution of both mutations.

Introduction

Recently, we reported a mutation in clotting factor II (prothrombin) that was associated with plasma levels of prothrombin and with the risk of deep-vein thrombosis [1]. The single base substitution (G to A) at position 20210 [2] of the 3’-untranslated region of the prothrombin gene was found in 18 percent of probands of thrombophilic families, six percent of unselected consecutive patients with deep-vein thrombosis and 2 percent of healthy controls [1]. Thus, carriership of this mutation led to a three-fold increased risk of venous thrombosis [1].

The mutation also affects the risk of arterial disease: among young women we found a four-fold increased risk of myocardial infarction among carriers of the factor II 20210A allele [3], while among men the risk was increased 1.5-fold [4].

Several recent reports, mainly in the form of meeting abstracts and presentations, have addressed the venous and arterial risk increase in other populations [5-11]. One of the problems with the studies is that the relatively low prevalence of the mutation in the general population leads to large uncertainties in the risk estimates. Moreover, it is possible that the prevalence depends on ethnicity and geography, as was found for the factor V Leiden mutation.

Therefore, we decided to combine our data on the frequency of the factor II 20210A variant in the general population, first, to arrive at a summary allele frequency estimate, and secondly, to examine whether there is heterogeneity in its distribution.

Methods

At the 11 centres from nine different countries, testing was performed for prothrombin 20210 G to A carriership in healthy individuals. The origin of each study group is listed in Table 1. Most centres were in Europe and the Middle East, and ranged from Scandinavia to the Mediterranean. In addition, we included a study from South-America (Campinas, Brazil) and from North-
Table 1  Numbers and origin of the tested individuals per centre

<table>
<thead>
<tr>
<th>Centre</th>
<th>n</th>
<th>Origin of tested individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leiden [4]</td>
<td>1760</td>
<td>medical controls (n=646, n=291), population controls (n=474), blood donors (n=249), hospital staff (n=105)</td>
</tr>
<tr>
<td>Tel Aviv [17]</td>
<td>1081</td>
<td>population controls1</td>
</tr>
<tr>
<td>Amsterdam [18]</td>
<td>400</td>
<td>hospital staff (n=272), population controls (n=138)</td>
</tr>
<tr>
<td>Paris [6]</td>
<td>398</td>
<td>medical controls1</td>
</tr>
<tr>
<td>Malmö [7]</td>
<td>282</td>
<td>blood donors (n=116), medical controls (n=166)</td>
</tr>
<tr>
<td>Vienna [8]</td>
<td>213</td>
<td>population controls (n=111), newborns (n=102)</td>
</tr>
<tr>
<td>Ferrara [9]</td>
<td>176</td>
<td>population controls</td>
</tr>
<tr>
<td>Manchester [10]</td>
<td>164</td>
<td>blood donors</td>
</tr>
<tr>
<td>Sheffield [11]</td>
<td>150</td>
<td>blood donors (n=96), population controls (n=54)</td>
</tr>
<tr>
<td>Brazil [18]</td>
<td>522</td>
<td>population controls (n=83), newborns (n=205), hospital staff (n=144)</td>
</tr>
<tr>
<td>United States [3]</td>
<td>384</td>
<td>population controls</td>
</tr>
</tbody>
</table>

1 orthopedic surgery patients (n=546), rheumatoid arthritis patients (n=291)
2 from various ethnic groups: Ashkenazi, North-African, Middle-Eastern (Iraqi and Iranian), Yemenite and Ethiopian Jews, and Arabs
3 medical check-up centre visitors, excluding those with cardiovascular disease
4 individuals who underwent orthopedic surgery (n=142), or gave blood samples for various reasons (n=24), excluding those with a history of cardiovascular disease
5 from three regions with different ethnic background: Amazonian Indians (n=83), Caucassians (n=295, Campinas, south-east), and with a mainly African descent (n=144, Bahia, north-east)

The selection of individuals varied between the various studies. In most cases, an effort was made to include healthy individuals, as a sample from the population. These samples ranged from hospital employees, to blood donors, newborns, and various groups of individuals visiting health care providers (‘medical control groups’) and, finally, formal control groups from the general population (Table 1). In none of the centres, individuals were selected in a way that would lead to preferential inclusion of individuals with thrombotic disease, while in most centres those with a history of cardiovascular disease were excluded. Approximately equal numbers of both sexes were included.

All centres except one used a strategy for the detection of the 20210 A allele similar to the one from the original report [1]. Leiden, Campinas, Amsterdam, Seattle, Malmö, Vienna, and Manchester used amplification primers exactly as described before [1]. Tel-Aviv, Paris, and Sheffield used primers that differ from the original but that still use the concept of introducing a Hind III recognition site with a mutagenic primer. The sequences of these primers and the reaction conditions can be obtained from the respective authors. Each centre reported that their local protocol was robust, which indicates that primer choice is not critical in the assay for the prothrombin mutation. Ferrara used allele specific amplification (ASA) to discriminate the prothrombin alleles. Two allele-specific primers, 5’-CTGGGACCATGGAAGCT-3’ (nucleotides 20227-20210) and 5’-CTGGGAGCATGGAAGCTT-3’ (nucleotides 20227-20210) were used as reverse primers in combination with the forward primer 5’-GGGAAATATGCTCTCTACA-3’ (nucleotides 20035-20054). The presence of an additional mismatch in the ASA primers increased selectivity of the ASA.

We categorized the prevalence of carriers of the prothrombin 20210 A-allele per centre, and pooled the estimates by two methods: first, by calculating an average weighted for the number of carriers per centre. This average gives most weight to the more precise estimates, since the variance, under Poisson assumptions, depends on the number of carriers. This is the appropriate method when it is assumed that the ‘true’ allelic prevalence is the same in all study groups, and that all observed variation in prevalences is random. This precision-weighted average is not the appropriate approach when the allelic prevalences are not constant. We assessed homogeneity of the prevalences by Poisson modeling of the prevalence rates and comparing the model with only the constant, to the saturated model with a dummy variable for centre, with the likelihood ratio statistic. As a second approach we calculated an unweighted average of the prevalence estimates (ie, the average with equal weights, which is the straight mean of the prevalence estimates). This unweighted straight average is more appropriate when homogeneity cannot be assumed. Prompted by the reports on a north-south difference in the prevalence of another common prothrombotic mutation, factor V Leiden [12], we stratified the analysis by geography into northern and southern European countries (the latter including the Middle-East).

For an analysis by ethnicity, we grouped together African-Americans from the United States and Brazil, and Ethiopian Jews from Israel as individuals with an African descent. Native-Americans, i.e., American Indians from north-western United States and the Amazon region in Brazil, were grouped together as individuals with an Asian background.

Confidence intervals for individual prevalence estimates were based on exact Poisson limits [13] and for pooled estimates on the normal approximation of the Poisson distribution.

Results

In the 11 centres, a total of 5527 individuals were tested. The total number of individuals per centre varied from 150 to 1760. Among these 5527 individuals, 111 heterozygous carriers of prothrombin 20210A were identified. No homozygous individuals were found. The number of carriers varied from 1 to 35 per centre, and the prevalence of carriage ranged from 0.7 percent to 4.0 percent (Fig. 1).

The overall prevalence was 2.3 percent (CI 95% 1.9 to 2.6%), when a weighted average was calculated. The variation of the prevalence estimates appeared to be more than would be expected by random variation around one underlying mean (LRS = 16.9, p = 0.08). Therefore, we calculated the average with equal weights; this straight average of prevalences was 2.0 percent (CI 95% 1.4 to 2.6%).

There was a clear relationship of the prevalence with the geographic latitude in Europe (including Israel): in the centres north of 50º N (Malmö, Manchester, Sheffield, Amsterdam, Leiden) there were 45 carriers among 2766 individuals tested, yielding a precision-weighted prevalence of 1.7 percent (CI 95% 1.3 to 2.2%); in the centres located...
south of 50°N (Paris, Vienna, Ferrara, Tel Aviv) we found 55 carriers among a total of 1868, yielding a prevalence of 3.0 percent (CI95 2.3 to 3.7%). So, the prevalence of the prothrombin variant was nearly twice as common in the southern as in the northern regions (χ² = 9.05, df = 1, p = 0.003). As can be seen in the figure, where the centres are shown in geographical order, in each of the four centres south of 50°N the prevalence estimate was higher than in each of the five centres north of 50°N.

Three centres included non-Caucasians: Brazil, Seattle and Tel-Aviv, which allowed a separate analysis of individuals with a different ethnic background. Among individuals with an African background, 2 carriers of factor II 20210A were found among 300 individuals (0/9 in Seattle, 2/144 in Bahia, Brazil, and 0/147 among Ethiopian Jews in Israel). Taken together, this accounts for a prevalence of carriage of only 0.67 percent (CI95: 0.08 to 2.4%, comparison with Caucasians χ² =3.02, p = 0.08 ). Among 103 Native Americans, ie, individuals with an Asian background (20 from Seattle, 83 from the Amazon region in Brazil) no carrier was detected (prevalence CI95: 0 to 3.6%, comparison with Caucasians χ² =2.24, p = 0.13).

Discussion

We have combined the data on the prevalence of carriage of the prothrombin 20210A variant from 11 centres, including a total of 5527 healthy individuals among whom 111 carried the variant. The estimate of the overall prevalence, under the assumption of homogeneity, was 2.3 percent (CI95 1.9 to 2.6%). The straight average of the prevalences was 2 percent (CI95 1.4-2.6%). We did not find any homogeneous individuals. This is not surprising, since with an allele frequency of 1 percent, we would expect homozygotes to occur in only 1 in 10,000.

The assumption of homogeneity did not appear true. Within Europe, there was an association with geographical location, with higher prevalences in the southern than in the northern countries. In southern Europe/Middle East, the prevalence was 3.0 percent (CI95 2.3 to 3.7%), and in northern Europe it was 1.7 percent (CI95 1.2 to 2.2%). This distribution in Europe is different to that reported for factor V Leiden, which has a high prevalence in northern Europe, especially in southern Sweden, and a low prevalence in Italy [12]. It has been hypothesized that such geographical differences might be the result of geographical differences in other risk factors, and thus by differences in genetic fitness and selection associated with gene-environment interaction. The finding of a very different geographical distribution for the prothrombin variant renders these explanations less likely. Probably, founder effects have played a much more important role. Interestingly, both factor V Leiden and prothrombin 20210A appear common in the Middle-East [14] and in Cyprus [9,15].

We have combined data from centres that used different criteria to recruit individuals, which raises questions about the comparability. Most centres excluded individuals with a history of thrombosis, or recruited blood donors and volunteers amongst whom such a history is unlikely. Although this would lead to lower estimates than obtained from a theoretically ideal study group of consecutive newborns, this difference is immaterial. Selection bias leading to overestimation would have occurred if for some reason individuals with thrombotic disease had been preferentially included. This bias did not occur, since the medical controls either comprised patients with disorders that are not associated with prothrombotic mutations (rheumatoid arthritis, orthopedic trauma), or, individuals without a history of thrombosis.

Factor V Leiden is extremely rare among non-Caucasians, which is in accordance with the estimated age of the mutation of 21,000 to 34,000 years [16], ie, occurring after the divergence of Africans from non-Africans and Caucasians from Asians [16]. Although the number of non-Caucasians in our collaborative study was relatively small, we found only 0.67 percent prevalence of carriers among individuals with an African background, and no carriers among Native Americans.

In another recent report, no carriers were found among 40 Somalians [9]. These findings suggests a low prevalence of prothrombin 20210A among Africans and Asians, as has been reported also for factor V Leiden [15,16].

We conclude that prothrombin 20210A is a common prothrombotic genetic variant, that has a prevalence of carriage between one and four percent. There are geographic differences in this prevalence, with a higher frequency in southern than in northern Europe. In areas with a high prevalence this variant may contribute significantly to the occurrence of thrombotic disease in the population.

References


